Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema
Información
- DOI:
- https://doi.org/10.1002/14651858.CD007419.pub3Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 12 diciembre 2012see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Salud ocular y de la visión
- Copyright:
-
- Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Conceiving the review: MP, FM, GV
Designing the review: MP, FM, GV
Coordinating the review: MP
Data collection for the review
‐ Designing electronic search strategies: Cochrane Eyes and Vision Group editorial base
‐ Undertaking manual searches: MP, FM
‐ Screening search results: MP
‐ Organizing retrieval of papers: MP
‐ Screening retrieved papers against inclusion criteria: MP, FM, GV
‐ Appraising quality of papers: MP, FM, GV
‐ Extracting data from papers: MP, FM, GV
‐ Writing to authors of papers for additional information: MP, FM, GV
‐ Providing additional data about papers: MP, FM, GV
‐ Obtaining and screening data on unpublished studies: MP, FM, GV
Data management for the review
‐ Entering data into RevMan: MP, FM, GV
Analysis of data: MP, FM, GV
Interpretation of data
‐ Providing a methodological perspective: MP, FM, GV
‐ Providing a clinical perspective: MP, FM, GV
‐ Providing a policy perspective: MP, FM, GV
‐ Writing the review: MP, FM, GV
Providing general advice on the review: GV
Securing funding for the review: MP, FM, GV
Sources of support
Internal sources
-
Azienda Ospedaliero‐Universitaria Careggi & University of Florence, based on funding by the Tuscany Region, Italy.
External sources
-
No sources of support supplied
Declarations of interest
None known
Acknowledgements
The Cochrane Eyes and Vision Group (CEVG) created and executed the search strategies. We thank Maria Diener‐West, Catey Bunce and Paolo Lanzetta for their comments on the review and Anupa Shah for her assistance throughout the review process.
Wen Xing and Catey Bunce provided visual acuity data on BOLT study.
Dr. Oliver Zeitz and dr. Christopher James (Bayer HealthCare) provided additional data regarding DA VINCI.
Meagan Huggins provided clarification regarding randomisation process in DRCRnet.
Richard Wormald (Co‐ordinating Editor for CEVG) acknowledges financial support for his CEVG research sessions from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.
Version history
| Published | Title | Stage | Authors | Version |
| 2023 Jun 27 | Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis | Review | Gianni Virgili, Katie Curran, Ersilia Lucenteforte, Tunde Peto, Mariacristina Parravano | |
| 2018 Oct 16 | Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis | Review | Gianni Virgili, Mariacristina Parravano, Jennifer R Evans, Iris Gordon, Ersilia Lucenteforte | |
| 2017 Jun 22 | Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysis | Review | Gianni Virgili, Mariacristina Parravano, Jennifer R Evans, Iris Gordon, Ersilia Lucenteforte | |
| 2014 Oct 24 | Anti‐vascular endothelial growth factor for diabetic macular oedema | Review | Gianni Virgili, Mariacristina Parravano, Francesca Menchini, Jennifer R Evans | |
| 2012 Dec 12 | Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema | Review | Gianni Virgili, Mariacristina Parravano, Francesca Menchini, Massimo Brunetti | |
| 2009 Oct 07 | Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema | Review | Mariacristina Parravano, Francesca Menchini, Gianni Virgili | |
| 2009 Jul 08 | Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for diabetic macular oedema | Protocol | Mariacristina Parravano, Francesca Menchini | |
Differences between protocol and review
Differences between protocol and review in the first published version of this review
We have added LILACS to the list of databases which have been searched for this review. We have used a sensitivity analysis for the robustness of results in comparisons including only one trial according to a statistical technique derived from a recent publication (Borm 2009).
Changes in update 2012 compared to the protocol of the previous version
-
We have specified that studies comparing different anti‐VEGF drugs will also be included in this review, but intravitreal steroids will be excluded as they are the subject of another Cochrane Review. Moreover, we decided not to consider the comparison of bevacizumab with bevacizumab plus trimacinolone, which included two studies; in fact this comparison investigates the additional effect of triamcinolone rather than the benefit with anti‐VEGF drugs.
-
We have computed indirect comparison odds ratios (OR) of gain of 3+ and 2+ lines for bevacizumab and pegaptanib versus ranibizumab as the reference drug using random‐effects logistic regression.
